Arcadia Biosciences (RKDA) Stock Price, News & Analysis

Company Overview

Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.

Key Stats

• Today's Range: $4.45 to $4.94
• 50-Day Range: $3.05 to $5.10
• 52-Week Range: $2.40 to $10.31
• Volume: 41,544 shs
• Average Volume: 308,761 shs
• Market Capitalization: $6.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Buy

Arcadia Biosciences Stock Analysis - MarketRank™

Arcadia Biosciences scored higher than 42% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Arcadia Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Arcadia Biosciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Arcadia Biosciences is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arcadia Biosciences is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arcadia Biosciences has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.64% of the float of Arcadia Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Arcadia Biosciences has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Arcadia Biosciences has recently increased by 67.67%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arcadia Biosciences does not currently pay a dividend.

Dividend Growth

Arcadia Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.64% of the float of Arcadia Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Arcadia Biosciences has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Arcadia Biosciences has recently increased by 67.67%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Arcadia Biosciences has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Arcadia Biosciences this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for RKDA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Arcadia Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.80% of the stock of Arcadia Biosciences is held by insiders.

Percentage Held by Institutions

Only 17.73% of the stock of Arcadia Biosciences is held by institutions.

RKDA Stock Analysis - Frequently Asked Questions

How have RKDA shares performed this year?

Arcadia Biosciences' stock was trading at $5.92 at the start of the year. Since then, RKDA stock has decreased by 20.4% and is now trading at $4.7140.
View the best growth stocks for 2025 here.

How were Arcadia Biosciences' earnings last quarter?

Arcadia Biosciences, Inc. (NASDAQ:RKDA) posted its quarterly earnings data on Thursday, May, 8th. The basic materials company reported $1.90 EPS for the quarter, beating the consensus estimate of ($0.98) by $2.88. The basic materials company earned $1.20 million during the quarter, compared to the consensus estimate of $1.60 million. Arcadia Biosciences had a negative trailing twelve-month return on equity of 16.94% and a negative net margin of 38.34%.
Read the conference call transcript.

When did Arcadia Biosciences' stock split?

Shares of Arcadia Biosciences reverse split on the morning of Wednesday, January 24th 2018.The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Arcadia Biosciences IPO?

Arcadia Biosciences (RKDA) raised $66 million in an initial public offering on Friday, May 15th 2015. The company issued 8,200,000 shares at $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray served as the underwriters for the IPO.

How do I buy shares of Arcadia Biosciences?

Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Arcadia Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcadia Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), PayPal (PYPL), GE Aerospace (GE), Arista Networks (ANET), Advanced Micro Devices (AMD) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/02/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Agriculture
• Current Symbol: NASDAQ:RKDA
• CIK: 1469443
• Web: www.arcadiabio.com
• Phone: (530) 756-7077
• Fax: 530-756-7027
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.00
• High Stock Price Target: $6.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +28.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.04 million
• Net Margins: -38.34%
• Pretax Margin: -14.51%
• Return on Equity: -16.94%
• Return on Assets: -10.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.99
• Quick Ratio: 3.41

Sales & Book Value

• Annual Sales: $5.05 million
• Price / Sales: 1.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.56 per share
• Price / Book: 1.02

Miscellaneous

• Outstanding Shares: 1,370,000
• Free Float: 1,342,000
• Market Cap: $6.40 million
• Optionable: Not Optionable
• Beta: 0.50